To describe D-dimer levels in patients receiving direct oral anticoagulants with and without suspected recurrence of venous thromboembolism
ISTH Academy. Leung P. Jul 9, 2019; 264462; PB1271 Topic: Biomarkers of Thrombosis & Hemostasis
Patrick Leung
Patrick Leung
Access to Reserved content is available to attendees of the Congress until the end of the year and always available for full ISTH members.

Click here to join ISTH or renew your membership.

Abstract
Discussion Forum (0)
Rate & Comment (0)

PB1271

To Describe D-Dimer Levels in Patients Receiving Direct Oral Anticoagulants with and without Suspected Recurrence of Venous Thromboembolism

P. Leung, S. Chunilal
Monash Medical Center, Haematology, Clayton, Australia

Main Topic: Diagnostics and OMICs
Category: Biomarkers of Thrombosis & Hemostasis

Background: D-dimer testing is useful in assessing patients with suspected venous thromboembolism (VTE). However, the accuracy of D-dimer in the diagnosis of recurrent VTE in patients receiving direct oral anticoagulants (DOACs) is unknown.
Aims: To describe D-dimer levels in patients receiving DOACs for VTE, with and without suspected recurrence of VTE.
Methods: A retrospective audit was performed of patients on DOAC therapy (specifically rivaroxaban and apixaban) for VTE. Patients with measureable anti Xa activity and a recorded D-dimer level were identified through the laboratory information system from April 2016 to February 2018 at Monash Medical Centre, Melbourne. D-dimer was tested with HemosIL D-dimer HS assay. Plasma anti-Xa levels were tested with the Stago anti-Xa kit using drug specific calibrators. All assays were performed on the ACL TOP 750 coagulometer. Patients with suspected recurrence where investigated with appropriate radiological testing.
Results: Thirty six patients were included, 13 of whom were investigated for suspected VTE recurrence. Patient demographics, DOAC and D-dimer levels are displayed in table 1. D-dimer was above 0.23mg/L ( cut-point for VTE) in 2/2 patients with confirmed recurrence and below 0.23mg/L in 8/9 those without recurrence (Sensitivity 100% (95% CI 34-100%) and Specificity 88% (95% CI 56-98%) Figure 1. In those without suspected recurrence 7/23 (30%) had a D-dimer above 0.23mg/L.
Conclusions: In patients with measureable anti-Xa level of DOACs, D-dimer levels for those with suspected recurrence was not universally suppressed and was positive in the 2 patients with confirmed recurrence. Similarly D-dimer levels were above 0.23mg/L in 30% of patients without suspected recurrence. These pilot data suggest D-dimer should be tested prospectively as a marker for recurrence even in the presence of measureable anti-Xa activity.


  Suspected VTE recurrence No VTE recurrence p-value
Number 13 23 -
Age, median (IQR) 62.0 (37.0-72.5) 56.0 (45.0-66.0) NS
Female, n (%) 9 (69.2) 12 (52.1) NS
  Anti-Xa level (ng/ml) (median, IQR) Anti-Xa level (ng/ml) (median, IQR)  
Rivaroxaban 169.27 (99.38 - 288.83) 119.30 (42.10 - 218.70) NS
Apixaban 120.60 (69.40 - 234.00) 78.70 (47.90 - 214.33) NS
  D-dimer (mg/L) (median, IQR) D-dimer (mg/L) (median, IQR)  
Rivaroxaban 0.23 (0.14 - 1.19) 0.11 (0.06 - 0.25) NS
Apixaban 0.12 (0.08 - 0.22) 0.15 (0.08 - 0.46) NS
[Table 1. Patient demographics, anti-Xa and D-dimer levels for those with and without suspected VTE recurrence.]




[Figure 1. ]

Code of conduct/disclaimer available in General Terms & Conditions

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies